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RENAL C4D DEPOSITION IS A MARKER OF HEMATOPOIETIC STEM CELL
TRANSPLANT (SCT)-ASSOCIATED THROMBOTIC MICROANGIOPATHY
(TMA)
Laskin, B.L., Goebel, J., Yin, H.J., Luo, G., Khoury, J.C., Davies, S.M.,
Jodele, S. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
C4d is a marker of classical complement activation by tissue spe-
cific antibodies (abs) or endothelial damage. Currently, peritubular
capillary (PTC) C4d deposition aids in the diagnosis (dx) of ab me-
diated kidney transplant rejection (AMR). An uncontrolled case se-
ries reported PTC and glomerular C4d staining in patients with
SCT-TMA (Mii et al, Path Int 2011). Expanding on these find-
ings, we hypothesized that renal tissue from patients with SCT-
TMA would more frequently show C4d deposition compared to
controls.
Methods: Retrospective analysis of all renal biopsy and autopsy
specimens from pediatric patients undergoing SCT at our institu-
tion. Using histological criteria alone, patients were divided into
TMA and non-TMA (control) groups. C4d staining was performed
by immunohistochemistry on formalin-fixed, paraffin-embedded tis-
sue and was evaluated on arterioles, PTCs, glomeruli, and tubular
basement membranes. Specifically, rabbit anti-human C4d poly-
clonal ab was applied to sections and C4d was independently graded
(diffuse: 50-100%; focal: 5-50%; rare: 1-5%; negative: 0%) by two
pathologists, blinded to each subject’s underlying dx.
Results: 20 total specimens were identified (19 subjects). Of these, 8
specimens (7 subjects) had histologic evidence of TMA (5 biopsy, 3
autopsy). 1 TMA subject had both a biopsy and autopsy with similar
findings, therefore only the autopsy findings are included. The 12
SCT recipient autopsies without TMA served as controls. Diffuse
and focal arteriolar C4d staining was far more common in TMA
specimens compared to controls (71.4% versus 8.3%, p 5 0.01).
PTC C4d staining was present in just under half of TMA samples
and was absent in controls (p 5 0.04). Glomerular C4d staining
was similar in both groups and tubular basement membrane staining
was rare.
Conclusions: This is the first report of arteriolar C4d deposition in
SCT-TMA, implicating localized complement fixation due to as yet
unidentified abs or ab-independent direct endothelial damage in the
pathogenesis of TMA. PTC C4d staining was found only in TMA,
while glomerular staining was non-specific as it was similar in bothTable. C4d Deposition in TMA
Histology proven
TMA (n 5 7) Control (n 5 12) p-value*
Pathology Results
Arteriolar C4d+ 5/7 (71.4%) 1/12 (8.3%) 0.01
PTC C4d+ 3/7 (42.9%) 0/12 (0%) 0.04
Glomerular capillary
C4d+
4/7 (57.1%) 10/12 (83.3%) 0.30
Tubular basement
membrane C4d+
2/7 (28.6%) 0/12 (0%) 0.12
Clinical Results
Age (years) 3.6 (1.7-4.5)
[0.6-4.9]
3.2 (1.4-17.1)
[0.9-28.1]
0.55
Gender (male) 3/7 (42.9%) 8/12 (66.7%) 0.38
Specimen day
post-SCT
237 (43 - 631)
[19 - 2281]
172 (78 - 253)
[9 - 887]
0.50
Malignancy 5/7 (71.4%) 2/12 (16.7%) 0.03
Immunodeficiency 1/7 (14.3%) 9/12 (75.0%) 0.03
Bone marrow failure 1/7 (14.3%) 1/12 (8.3%) 0.03
Allogeneic 2/7 (28.6%) 11/12 (91.7%) 0.01
Autologous 5/7 (71.4%) 1/12 (8.3%) 0.01
GVHD in those at
risk (allogeneic)
1/2 (50%) 3/11 (27.3%) 1.00
Viral infection 4/7 (57.1%) 4/12 (33.3%) 0.38
Dialysis 6/7 (85.7%) 5/12 (41.7%) 0.15
*from Fisher’s exact test for categorical variables and Wilcoxon Rank
sum for continuous variables; data expressed as n (%) or median
(25th-75th percentile) [range].groups. Although the preferential arteriolar C4d staining is incom-
pletely understood, it may identify a renal site of injury, explaining
the dramatic hypertension often seen in TMA. Future research
should assess if patients with SCT-TMA and renal C4d deposition
will benefit from therapies currently used to treat kidney transplant
AMR.
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NA€ıVE CD19-SPECIFIC T CELLS EXHIBIT SUPERIOR PROLIFERATION AND
POTENTIAL FOR ADOPTIVE IMMUNOTHERAPY
Singh, H.1, Figliola, M.J.1, Dawson, M.J.1, Zhang, L.1, Yang, G.1,
Huls, H.1, Kelly, S.1, Kebriaei, P.2, Champlin, R.E.2, Cooper, L.J.N.1
1U.T.M.D. Anderson Cancer Center, Houston, TX; 2U.T. M.D. Ander-
son Cancer Center, Houston, TX
T cells in human peripheral blood can be characterized as na€ıve
(TN), central memory (TCM) and effector memory (TEM). We and
others seek to define the best cellular substrate for genetic modifica-
tion and expression of tumor-specific immunoreceptors, such as
a CD19-specific chimeric antigen receptor (CAR) for adoptive
transfer in pediatric and adult patients after hematopoietic stem
cell transplantation. Na€ıve-derived effector cells (TEFF[sup]N[/sup])
are an attractive T-cell population for adoptive immunotherapy as
they confer improved anti-tumor activity in a mouse (pmel-1 tumor)
model. Therefore, we determined the relative frequency of TN
(CD62L+CD45RAneg), TCM (CD62L
+CD45RAneg), TEM
(CD62LnegCD45RAneg) and TEMRA (CD62L
negCD45RA+) subsets
in peripheral blood mononuclear cells (PBMC) from normal
healthy donors (n 5 21) and observed an abundance of circulating
TN cells compared toTCM (p\0.001), andTEM (p\0.05). To deter-
mine if we could retrieve CAR+ TEFF[sup]N[/sup] and propagate them
ex vivo to clinically-appealing numbers, PBMC were sorted into
three T-cell subsets and genetically modified by electroporation
to express a CD19-specific CAR using the Sleeping Beauty (SB)
DNA plasmid system. Our artificial antigen presenting cells
(aAPC) were then used to numerically expand CD19-specific T cells
in a CAR-dependent manner.We observedCD19-specific T cells in
all subsets, with total cell numbers higher in TEFF[sup]N[/sup] than
TEFF[sup]CM[/sup] or TEFF[sup]EM[/sup]. These increased cell numbers
were explained by the enhanced proliferative capacity of TEFF[sup]N
[/sup]. Although specific cytolytic ability was diminished for CAR
+
TEFF[sup]N[/sup], in contrast to the other T-cell subsets, they secreted
more IFN-g in response to CD19. These data suggest that TN in
PBMC can be selectively electroporated and propagated using our
current platforms (SB and aAPC system) for generating clinical-
grade CAR+ T cells.
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EXPOSURE OF EARLY TRAINEES TO BONE MARROW TRANSPLANT
LEADS TO HIGHER BMT PHYSICIAN RECRUITMENT
Shereck, E.1, Shenoy, S.2, Pulsipher, M.A.3, Burns, L.4, Bracey, A.5,
Chell, J.6, Snyder, E.7, Nemecek, E.1 1Oregon Health & Science Univer-
sity, Portland, OR; 2Washington University School of Medicine, St. Louis,
MO; 3University of Utah, Salt Lake City, UT; 4University of Minnesota,
Minneapolis, MN; 5University of Texas-Houston, Houston, TX; 6Na-
tional Marrow Donor Program, Minneapolis, MN; 7Yale School of Med-
icine, New Haven, CT
The National Marrow Donor Program (NMDP) projects the
need for allogeneic unrelated blood and marrow transplants
(BMT) in the United States is 10,000 per year. While the
NMDP is preparing to facilitate that number by 2015, there are
a number of barriers to meeting this need including recruiting ad-
ditional health care personnel including BMT providers. To learn
how best to recruit BMT physicians, we sought to understand why
practicing BMT physicians chose to enter BMT, and why others
did not. We conducted a web-based survey amongst Pediatric He-
matology/Oncology (PHO) and BMT physician providers and
trainees to determine the factors influencing their decision to
choose or not choose a career in BMT. There were 259 respon-
dents (48% male, 74% of Caucasian origin); 94 identified as
BMT physicians, 112 as PHO physicians and 53 as PHO trainees.
PHO and BMT providers spent an average of 53% in clinical
